title: Potential effect of zoledronate therapy in heavy proteinuria.
authors.forename: N
authors.initials: N
authors.lastname: Gokden
authors.forename: M
authors.initials: M
authors.lastname: Zangari
authors.forename: F
authors.initials: F
authors.lastname: Elici
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.forename: J
authors.initials: J
authors.lastname: Kumar
mesh_terms: D001706:Biopsy; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000009:adverse effects*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D011507:Proteinuria / Q000139:chemically induced* / Q000188:drug therapy; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D007093:Imidazoles; D000077211:Zoledronic Acid; D011241:Prednisone